Bone Marrow TransplantationTransplantation, HomologousHematopoietic Stem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningBone MarrowTransplantation, AutologousHematologic NeoplasmsHematopoietic Stem CellsWhole-Body IrradiationBone Marrow CellsTransplantation ChimeraTissue DonorsStem Cell TransplantationLeukemiaBusulfanGraft vs Leukemia EffectAnemia, AplasticHistocompatibilityHistocompatibility TestingGraft SurvivalRecurrenceGraft vs Tumor EffectTreatment OutcomeLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcutePeripheral Blood Stem Cell TransplantationRemission InductionPrecursor Cell Lymphoblastic Leukemia-LymphomaRetrospective StudiesLymphocyte TransfusionImmunosuppressive AgentsHepatic Veno-Occlusive DiseaseMyelodysplastic SyndromesTransplantation, IsogeneicHematologic DiseasesCyclophosphamideLymphocyte DepletionAcute DiseaseCombined Modality TherapyMyeloablative AgonistsChimerismHLA AntigensLiver TransplantationTime FactorsHematopoiesisTransplantation ImmunologyT-LymphocytesSurvival AnalysisCytomegalovirus InfectionsMice, Inbred C57BLSurvival RateLeukemia, MyeloidStem CellsBone and BonesLeukocyte TransfusionCord Blood Stem Cell TransplantationImmunosuppressionRadiation ChimeraVidarabineSevere Combined ImmunodeficiencyDisease-Free SurvivalBone Marrow PurgingGraft RejectionAllograftsFollow-Up StudiesSiblingsGraft vs Host ReactionCyclosporineKidney TransplantationMultiple MyelomaFlow CytometryFatal OutcomeMinor Histocompatibility AntigensNeoplasm, ResidualAntineoplastic Combined Chemotherapy ProtocolsAntilymphocyte SerumCytarabineSalvage TherapyOpportunistic InfectionsAntigens, CD34Lymphoproliferative DisordersChimeraLymphoma, Non-HodgkinImmunocompromised HostPrognosisCell DifferentiationHematopoietic Stem Cell MobilizationBone Marrow DiseasesCystitisNuclear FamilyCytomegalovirusMice, Inbred BALB CGranulocyte Colony-Stimulating FactorColony-Forming Units AssayBlood Group IncompatibilityGanciclovirRisk FactorsLeukemic InfiltrationHeart Transplantation